Many of the trials used in this analysis were treat‐to‐target, which minimize differences in HbA1c. In the NMAs, statistical significance was severely undermined by the wide credible intervals. Despite these limitations, point estimates of HbA1c were used to rank the insulins and formed the basis of NG17 guidance. This study queries whether such analyses should be used to make specific clinical recommendations (Diabetic Medicine)
Diabetes News
Tag: Type 1 Diabetes
The increased risk of microvascular complications in South Asians with type 1 diabetes is influenced by migration: results from the UK–India multi‐ethnic migration study
In this hypothesis‐generating study, we report that South Asian ethnicity is associated with greater risk of diabetic kidney disease and retinopathy, and lower risk of neuropathy than white European ethnicity (Diabetic Medicine)
Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
Switching patients with type 1 diabetes to IDeg from other basal insulins was associated with relevant improvements in metabolic control and glycemic variability without weight gain; the risk of hypoglycemic episodes also significantly declined (Diabetes Therapy)
Hypoglycemic Confidence in the Partners of Adults with Type 1 Diabetes
HC is an important facet of the experiences of T1D partners. It is related to, yet distinct from, hypoglycemic fear. The Partner-HCS is a reliable, valid method for assessing HC in partners of T1D adults (Diabetes Technology and Therapeutics)
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (NEJM)
Characteristics of newly diagnosed adults with type 1 diabetes in the UK and evolution of glycaemic control, body mass index and Charlson comorbidity index over the first 5 years after diagnosis
More intensive support to reach and maintain glycaemic targets soon post-diagnosis, while avoiding weight gain, and prevention and optimal management of comorbidities are warranted (Primary Care Diabetes)
Factors associated with glycaemic control in adults with Type 1 diabetes: a registry‐based analysis including 7601 individuals from 34 centres in Norway
We present representative national data on factors that were associated with glycaemic control. A better understanding and awareness of these factors, together with technological advances in diabetes management, could lead to more personalized management strategies, better glycaemic control and a lower risk of diabetes complications (Diabetic Medicine)
Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study
Islet transplantation with the Edmonton protocol can provide 10-year markedly improved metabolic control without SHEs in three-quarters of patients with type 1 diabetes, kidney transplanted or not (Diabetes Care)
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump (NEJM)
Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study
rtCGM was superior to SMBG in reducing A1C, hypoglycemia, and other end points in individuals with T1D regardless of their insulin delivery method. rtCGM+MDI can be considered an equivalent but lower-cost alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy (Diabetes Care)
IDF Diabetes Atlas: Worldwide Estimates of Incidence, Prevalence and Mortality of Type 1 Diabetes in Children and Adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Worldwide estimates of numbers of children and adolescents with type 1 diabetes continue to increase (Diabetes Research and Clinical Practice)
Dapagliflozin with insulin for treating type 1 diabetes
Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a body mass index (BMI) of at least 27 kg/m2 (NICE)
HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study
Risk of retinopathy and nephropathy did not differ at HbA1c levels <6.5% but increased for severe hypoglycaemia compared with HbA1c levels 6.5-6.9%. The risk for severe complications mainly occurred at HbA1c levels >8.6%, but for milder complications was increased at HbA1c levels >7.0% (BMJ)
Educational and Health Outcomes of Children Treated for Type 1 Diabetes: Scotland-Wide Record Linkage Study of 766,047 Children
Children with type 1 diabetes fare worse than their peers in respect of education and health outcomes, especially if they have higher mean HbA1c. Interventions are required to minimize school absence and ensure that it does not affect educational attainment (Diabetes Care)
Commissioning Standard: Dental Care for People with Diabetes
This commissioning standard document supports commissioners in NHS England and NHS Improvement with the implementation of a standardised framework for the local commissioning of dental services for people with diabetes (type 1 and type 2) and people with non-diabetic hyperglycaemia (NDH)
Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes
UCPCR is a practical and noninvasive marker that can distinguish between TIDM and T2DM or monogenic diabetes. reflects severe impaired beta cell function and the need for insulin or secretagogue therapy in T2DM patients (Journal of Diabetes Research)
The future is now: SGLT2 inhibitors and type 1 diabetes – what about exercise?
This novel drug class, which has received wide attention in its glucose-lowering and cardiovascular-protective properties in the management of type 2 diabetes, also bears potential for individuals with T1D who are struggling with achieving glycaemic targets
Dapagliflozin with insulin for treating type 1 diabetes
Recommendations (NICE)
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Low-dose SGLTi profile was the favored adjunct-to-insulin therapy by persons with T1D (Diabetes Care)
Electrophysiological Characterization of Neuropathy Complicating Type 1 Diabetes Mellitus
These findings signify generation of a protocol for early screening of neuropathy in children with type 1 diabetes (Journal of Diabetes Research)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 17
- Next Page »
Glycosmedia is also available as an App: